CD8A and cancer: Adoptive T-cell immunotherapy for cancer, which was based upon the adoptive transfer of in vitro active tumor-specific CD8+ T-cells into cancer patients, previously achieved only some degree of success [50, 51], mostly due to their very short lifespan in vivo [52, 53].